{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:03Z","timestamp":1792269483332,"version":"4.4.0"},"reference-count":53,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005632","name":"WUM AID project Academy of Innovative Didactic of the Medical University of Warsaw","doi-asserted-by":"publisher","award":["03.05.00-00-Z088\/17-00"],"award-info":[{"award-number":["03.05.00-00-Z088\/17-00"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"WUM AID project Academy of Innovative Didactic of the Medical University of Warsaw","doi-asserted-by":"publisher","award":["NOR\/POLNOR\/TEPCAN\/0057\/2019-00"],"award-info":[{"award-number":["NOR\/POLNOR\/TEPCAN\/0057\/2019-00"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Norwegian Financial Mechanisms 2014\u20132021\/POLNOR 2019 (EEA and Norway grants)","doi-asserted-by":"publisher","award":["03.05.00-00-Z088\/17-00"],"award-info":[{"award-number":["03.05.00-00-Z088\/17-00"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Norwegian Financial Mechanisms 2014\u20132021\/POLNOR 2019 (EEA and Norway grants)","doi-asserted-by":"publisher","award":["NOR\/POLNOR\/TEPCAN\/0057\/2019-00"],"award-info":[{"award-number":["NOR\/POLNOR\/TEPCAN\/0057\/2019-00"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>BRAF inhibitors have improved the treatment of advanced or metastatic melanoma in patients that harbor a BRAFT1799A mutation. Because of new insights into the role of aberrant glycosylation in drug resistance, we designed and studied three novel vemurafenib derivatives possessing pentose-associated aliphatic ligands\u2014methyl-, ethyl-, and isopropyl-ketopentose moieties\u2014as potent BRAFV600E kinase inhibitors. The geometries of these derivatives were optimized using the density functional theory method. Molecular dynamic simulations were performed to find interactions between the ligands and BRAFV600E kinase. Virtual screening was performed to assess the fate of derivatives and their systemic toxicity, genotoxicity, and carcinogenicity. The computational mapping of the studied ligand\u2013BRAFV600E complexes indicated that the central pyrrole and pyridine rings of derivatives were located within the hydrophobic ATP-binding site of the BRAFV600E protein kinase, while the pentose ring and alkyl chains were mainly included in hydrogen bonding interactions. The isopropyl-ketopentose derivative was found to bind the BRAFV600E oncoprotein with more favorable energy interaction than vemurafenib. ADME-TOX in silico studies showed that the derivatives possessed some desirable pharmacokinetic and toxicologic properties. The present results open a new avenue to study the carbohydrate derivatives of vemurafenib as potent BRAFV600E kinase inhibitors to treat melanoma.<\/jats:p>","DOI":"10.3390\/molecules28135273","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:54:23Z","timestamp":1688950463000},"page":"5273","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-0329","authenticated-orcid":false,"given":"Teresa","family":"\u017bo\u0142ek","sequence":"first","affiliation":[{"name":"Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02 097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mazurek","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Food Science, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02 097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-1771","authenticated-orcid":false,"given":"Ireneusz P.","family":"Grudzinski","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Food Science, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02 097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.6691137","article-title":"The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4","volume":"223","author":"Bonner","year":"1984","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"775","article-title":"Vemurafenib: An evidence-based review of its clinical utility in the treatment of metastatic melanoma","volume":"8","author":"Swaika","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: The first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-08-0431","article-title":"Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas","volume":"7","author":"Smalley","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/jid.2015.105","article-title":"MITF Modulates Therapeutic Resistance through EGFR Signaling","volume":"135","author":"Ji","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1038\/cddis.2013.441","article-title":"AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma","volume":"4","author":"Hu","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Salangsang","year":"2013","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1758835919830826","DOI":"10.1177\/1758835919830826","article-title":"Combined targeted therapy and immunotherapy in melanoma: A review of the impact on the tumor microenvironment and outcomes of early clinical trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rager, T., Eckburg, A., Patel, M., Qiu, R., Gantiwala, S., Dovalovsky, K., Fan, K., Lam, K., Roesler, C., and Rastogi, A. (2022). Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. Cancers, 14.","DOI":"10.3390\/cancers14153779"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.COT.0000724720.31219.70","article-title":"New BRAF inhibitor shows promise in a variety of cancers","volume":"42","author":"Froelich","year":"2020","journal-title":"Oncol. Times"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-017-0684-x","article-title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation","volume":"16","author":"Tutuka","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3727\/096504017X15031557924123","article-title":"beta-1,3-Galactosyl-O-Glycosyl-Glycoprotein beta-1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8\/A9-Mediated Cancer Motility","volume":"26","author":"Sumardika","year":"2018","journal-title":"Oncol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.18632\/oncotarget.22377","article-title":"Drug resistance related to aberrant glycosylation in colorectal cancer","volume":"9","author":"Very","year":"2018","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-4598-6-32","article-title":"N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma","volume":"6","author":"Kudo","year":"2007","journal-title":"Mol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"De Vellis, C., Pietrobono, S., and Stecca, B. (2021). The Role of Glycosylation in Melanoma Progression. Cells, 10.","DOI":"10.3390\/cells10082136"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nisiewicz, M.K., Kowalczyk, A., Sobiepanek, A., Jagielska, A., Wagner, B., Nowakowska, J., Gniadek, M., Grudzinski, I.P., Kobiela, T., and Nowicka, A.M. (2021). Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010439"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12032-019-1270-4","article-title":"N-Glycosylation in progression of skin cancer","volume":"36","author":"Tang","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/2193-1801-2-353","article-title":"An in silico evaluation of the ADMET profile of the StreptomeDB database","volume":"2","year":"2013","journal-title":"Springerplus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-002-0426-9","article-title":"Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis","volume":"58","author":"Thapar","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00113","DOI":"10.1002\/prp2.113","article-title":"A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma","volume":"3","author":"Goldinger","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-017-0523-7","article-title":"Clinical Pharmacokinetics of Vemurafenib","volume":"56","author":"Zhang","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","article-title":"How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations","volume":"13","author":"Sargsyan","year":"2017","journal-title":"J. Chem. Theory Comput."},{"key":"ref_37","unstructured":"Dassault Syst\u00e8mes BIOVIA (2016). Discovery Studio Modeling Environment, Release 2017, Dassault Syst\u00e8mes."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<553::AID-JCC3>3.0.CO;2-T","article-title":"Merck molecular force field 3. Molecular geometries and vibrational frequencies for MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J. Comput. Chem."},{"key":"ref_39","unstructured":"Hehre, W., and Ohlinger, S. (2022). Spartan 20 for Windows, Machintosh and Linux Tutorial and Users \u2019Guide, Wavefunction Inc."},{"key":"ref_40","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: The biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jcc.24259","article-title":"Flexible CDOCKER: Development and application of a pseudo-explicit structure-based docking method within CHARMM","volume":"37","author":"Gagnon","year":"2016","journal-title":"J. Comput. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of Simple Potential Functions for Simulating Liquid Water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular-Dynamics with Coupling to an External Bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J. Chem. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc Chem. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chandrasekaran, B., Abed, S.N., Al-Attraqchi, O., Kuche, K., and Tekade, R.K. (2018). Computer-Aided Prediction of Pharmacokinetic (ADMET) Properties, Elsevier. Dosage Form Design Parameters.","DOI":"10.1016\/B978-0-12-814421-3.00021-X"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17460441.2020.1696307","article-title":"The impact of chemoinformatics on drug discovery in the pharmaceutical industry","volume":"15","author":"Maggiora","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_49","unstructured":"(2020). ADMET Predictor, Simulations Plus. Version 10.1."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/mp300482w","article-title":"Predicting pharmacokinetic profiles using in silico derived parameters","volume":"10","author":"Hosea","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Savoia, P., Zavattaro, E., and Cremona, O. (2020). Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249730"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/13\/5273\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:08:05Z","timestamp":1760126885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/13\/5273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":53,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["molecules28135273"],"URL":"https:\/\/doi.org\/10.3390\/molecules28135273","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}